Comparison of Efficacy of Antithymocyte Globulin/antilymphocyte Globulin Combined with Cyclosporin A and Allogeneic Hematopoietic Stem Cell Transplantation in Treatment of Patients with Aplastic Anemia
Ji Yueru,Li Guohui,Liu Qiang,Chen Ren'an,Qin Weiwei,Liu Li
DOI: https://doi.org/10.3760/cma.j.issn.1673-419x.2018.06.002
2018-01-01
Abstract:Objective To analyze efficacy and safety of antithymocyte globulin (ATG)/antilymphocyte globulin (ALG) combined with cyclosporine A and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of patients with aplastic anemia (AA).Methods From February 2014 to February 2017,a total of 68 AA patients who were admitted to Department of Hematology,Tangdu Hospital,Fourth Military Medical University were included in this study.According to different treatment strategies,they were divided into ATG/ALG combined with cyclosporin A group (n=27) and allo-HSCT group (n=41).Clinical data of patients in two groups were analyzed retrospectively,and efficacy and treatment-related adverse reactions of patients in two groups were compared.Age,neutrophil count (ANC),platelet count,reticulocytes absolute count,hemoglobin (Hb) value,and follow-up period of patients in two groups were analyzed by two-sample t test or Mann-Whitney U test.Ratio of patients with severe aplastic anemia (SAA),good hematologic response rate,hematologic response rate,treatment-related adverse reaction rate,early case fatality ratio,total case fatality ratio,ratio of patuients with recurrence or progression were analyzed by x2 test or corrected x2 test.Overall survival (OS) rates and progression free survival (PFS) rates of patients in two groups were analyzed by Kaplan-Meier method and Log-rank test.The procedure of this study is accordance with the requirement of the revised World Medical Association Declaration of Helsinki in 2013.Informed consent was obtained from all participants.Results ① Gender of male and female composition ratio was 0.7∶1 in ATG/ALG combined with cyclosporine A group,and was lower than that of 2.2∶1 in allo-HSCT group,and the difference was statistically significant (x2 =5.052,P =0.025).There were no significant differences in average age,average ANC,median platelet count,median reticulocytes absolute count,median Hb value,and ratio of patients with SAA between 2 groups (P＞0.05).② Good hematological response rate (58.5％,24/41) and hematologic response rate (82.9％,34/41) of patients in allo-HSCT group were higher than those in ATG/ALG combined with cyclosporine A group,which were 14.8％ (4/27) and 51.9％ (14/27),and the differences were statistically significant (x2=12.850,P＜0.001;x2 =7.572,P=0.006).③ Incidence rate of treatment-related adverse reactions of patients in ATG/ALG combined with cyclosporin A group was 22.2％ (6/27),among which 4 cases had serum disease,2 cases had new lung infection,and 1 case had perianal infection.Incidence rate of treatment-related adverse reactions of patients in allo-HSCT group was 63.4％(26/41),among which 10 cases had new infections,16 cases had graft versus host disease (GVHD),10 cases had cytomegalovirus (CMV) infection,and 2 cases had Epstein-Barr virus (EBV) infection.There was significant difference in incidence rate of treatment-related adverse reactions of patients between two groups (x2 =11.090,P＜0.001).④ Early case fatality ratio,total case fatality ratio,ratio of patients with recurrence or progression of patients in ATG/ALG combined with cyclosporin A group were 3.7S％(1/27),3.7％(1/27) and 0 (0/27),respectively;and those indexes were 7.3％(3/41),12.2％ (5/41) and 7.3％(3/41) in allo-HSCT group,respectively.There were no statistically significant differences in early case fatality ratio,total case fatality ratio,ratio of recurrence or progression of patients between two groups (P＞0.05).⑤ Median follow-up period was 9.0 months (5.0-19.0 months) in ATG/ALG combined with cyclosporin A group,and 12.0 months (7.0-22.5 months) in allo-HSCT group,and the differences were not statistically significant (P＞0.05).Results of survival analysis showed that OS rates of patients in two groups were 96.3％ and 86.3％,and PFS rates were 92.4％and 84.0％,and both differences were not statistically significant (P＞O.05),respectively.Conclusions Clinical efficacy of ATG/ALG Combined with cyclosporin A in the treatment of AA patients was not as good as allo-HSCT,but its safety was higher than that of allo-HSCT treatment strategy.Applying allo-HSCT for AA treatment,prevention and treatment of transplant-related adverse reactions should be highly addressed.